We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Product Availability Update

Promega Manufacturing and Delivery Systems continue to be fully operational during the COVID-19 outbreak. Our teams are in regular contact with suppliers and distributors worldwide and are taking all steps necessary to address both demands for diagnostic tools and reliable delivery of all products as quickly as possible. Learn more

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

ADCC Reporter Bioassays, F Variant

MOA-Based Bioassay to Measure FcγRIIIa (F158) Function

  • No cell culture required
  • Quantitate impact of F158 polymorphism on Fc effector function

Choose a kit format

Choose an option

Catalog number selected: G9798

$ 3,780.00
Your price:
Add to Cart
This product is discontinued
ADCC Reporter Bioassays, F Variant
Core Kit/5 × Each Component
$ 3,780.00
Your price: Log in
Change Configuration
32454665-ADCC-overview-header

Specifically Quantitate the Effect of the FcγIIIa F158 Polymorphism

Fc receptor-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) by which antibodies target disease cells for elimination.

The ADCC Reporter Bioassays, F Variant use NFAT-mediated luciferase activity in effector cells as indicator of ADCC MOA, providing an alternative to traditional primary cell based assays for measuring the effect of biologics on ADCC activity. 

They are accurate, precise and stability-indicating and prequalified according to ICH guidelines, making them suitable for all stages of biologic research and development. 

32454665-ADCC-ghosted-bkground

The Pathway

The human FcyRIIIa gene displays a polymorphism in the position coding for amino acid residue 158. This translates to a higher affinity FcyRIIIa variant having a valine at amino acid 158 (V158 and a lower affinity FcyRIIIa variant carrying phenylalanine F158). Killing of target cells is an endpoint of this pathway activation and is used in classic ADCC bioassays, which use donor peripheral blood mononuclear cells (PBMC) or the natural killer (NK) cell subpopulation as effector cells isolated from blood donors with FcyRIIIa VV, VF or FF alleles.

These primary cells can be highly variable in response, are tedious to prepare and can result in high background readings. It is highly challenging to quantitatively evaluate the impact of FcyRIIIa polymorphism by classic in vitro ADCC bioassays. The ADCC Reporter Bioassay, F Variant, overcomes many of these pain points. 

The Workflow

Standard bioassay workflow with cultured cells
Improved bioassay workflow with thaw-and-use cells

Standardized Reagents Improve Results

  • Thaw-and-use cell format provides significant time and labor savings over traditional methods while reducing variability.
  • Kit includes all of the required reagents in standardized formats.
  • Easily amenable to high-throughput workflows.

The Assay Principle

The Fc Effector Reporter Bioassays use an alternative readout from traditional primary cell based assays: the FcγR and NFAT-mediated activation of luciferase activity in the effector cells. Primary cells are replaced with a Jurkat cell line stably expressing human FcγRIIIa and NFAT-induced luciferase.

10338MA-W

Luminescent Assay Monitors Fc Effector Activity

Following engagement with the Fc region of a relevant antibody bound to a Target Cell, ADCC Bioassay Effector Cells expressing FcγRIIIa F158 with transduce intracellular signals resulting in NFAT-mediated luciferase activity that can be easily quantified.

Assay Performance Data

Accuracy and Precision are critical to bioassays and development of biologics. The ADCC Reporter Bioassays are both accurate and precise. Accuracy is a measure of how close results are to a target or reference value. Precision is a measure of repeatability.
32454665-data-target1
Accurate, but not precise

Accuracy

Measure of ability to replicate a reference or “target” value.

32454665-data-target2
Precise, but not accurate

Interlab Precision

Measure of repeatability from multiple assays of the same homogeneous sample under the same operating conditions over a short time (same analyst; same lab; same day).

32454665-data-target3
Precise and accurate

Intermediate Precision

Measure of repeatability of multiple assays of the same homogeneous sample with different analysts or equipment or on different days (many people).

32454665-data-linear
Linear

Linearity

Ability of your assay to provide measured values at are proportional to the concentration of the sample.

ADCC Reporter Bioassay, F Variant Precision, Accuracy and Linearity

WIL2-S Target Cells

Accuracy


Expected
Relative Potency
Recovery
50% 87.7%
75% 90.4%
150% 95.1%
200% 103.1%

Repeatability (100% reference, %CV)


3.4%

Intermediate Precision (%CV)


6.2%

Linearity


r2 = 0.997(50 – 200% range)
y = 1.071x – 12.04

Raji Target Cells

Accuracy


Expected
Relative Potency
Recovery
50% 101.3%
75% 99.2%
150% 107.8%
200% 99.3%

Repeatability (100% reference, %CV)


5.7%

Intermediate Precision (%CV)


7.7%

Linearity


r2 = 0.993(50 – 200% range)
y = 1.071x + 0.596

The ADCC Reporter Bioassay is specific for FcγRIIIa-mediated (158F) ADCC

Use the ADCC Reporter Bioassay, F Variant to:

  • Demonstrate and/or confirm ADCC MOA (or lack thereof)
  • Measure antibody potency and stability
  • Determine the impact of antibody glycosylation and afucosylation on ADCC
  • Screen Antibodies
12449MA-web
For experimental details see Technical Manual #TM427.

Product Format

The Core Kit includes the ADCC Bioassay Effector Cells, Cell Culture Medium and Assay Reagents and is recommended for routine use with customer-defined antibody and target cells.
32454665-ADCC-product-format

Specifications

You are viewing: G9798 Change Configuration

What's in the box?

Item Part # Size

ADCC Bioassay Effector Cells, F Variant

G979A 5 × 1 vial

Low IgG Serum

G711A 5 × 4ml

RPMI 1640 Medium

G708A 5 × 36ml

Bio-Glo™ Luciferase Assay Buffer

G719A 5 × 10ml

Bio-Glo™ Luciferase Assay Substrate

G720A 5 × 1 vial

SDS

Choose language:

Download SDSPDF (303 KB) – English (United States)

Use Restrictions

Not For Medical Diagnostic Use.

Storage Conditions

Please see the Protocol for detailed storage instructions.

Patents and Disclaimers

NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.
This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) drug discovery and development of biologic drugs, (3) quality assurance testing of biologic drugs, and (4) product release assays for biologic drugs. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the Effector Cells or the luciferase gene stably transfected within the Effector Cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all determinations of luminescence activity of this product, or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

U.S. Pat. No. 10,077,244 and other patents.

Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

Specifications

You are viewing: G9790 Change Configuration

What's in the box?

Item Part # Size

ADCC Bioassay Effector Cells, F Variant

G979A 1 × 1 vial

Low IgG Serum

G711A 1 × 4ml

RPMI 1640 Medium

G708A 1 × 36ml

Bio-Glo™ Luciferase Assay Buffer

G719A 1 × 10ml

Bio-Glo™ Luciferase Assay Substrate

G720A 1 × 1 vial

SDS

Choose language:

Download SDSPDF (208 KB) – English (United States)

Use Restrictions

Not For Medical Diagnostic Use.

Storage Conditions

Please see the Protocol for detailed storage instructions.

Patents and Disclaimers

NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.
This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) drug discovery and development of biologic drugs, (3) quality assurance testing of biologic drugs, and (4) product release assays for biologic drugs. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the Effector Cells or the luciferase gene stably transfected within the Effector Cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all determinations of luminescence activity of this product, or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

U.S. Pat. No. 10,077,244 and other patents.

Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

Let's find the product that meets your needs.

Talk to a Scientist

Uwe

Uwe

Germany